| scholarly article | Q13442814 |
| P50 | author | Diana V. Pastrana | Q60320068 |
| P2093 | author name string | David J Fitzgerald | |
| Roberta Traini | |||
| Gal Ben-Josef | |||
| Antonella Antignani | |||
| Ashima K Sharma | |||
| Elizabeth Moskatel | |||
| P2860 | cites work | One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell | Q67390807 |
| Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin | Q73762009 | ||
| Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro | Q73769171 | ||
| Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins | Q79116890 | ||
| Effects of BCL-2 overexpression on the sensitivity of MCF-7 breast cancer cells to ricin, diphtheria and Pseudomonas toxin and immunotoxins | Q79332305 | ||
| Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies | Q80977096 | ||
| Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers | Q81038996 | ||
| Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression | Q84702932 | ||
| Intracellular signaling by the unfolded protein response | Q28250477 | ||
| Proapoptotic BAX and BAK regulate the type 1 inositol trisphosphate receptor and calcium leak from the endoplasmic reticulum | Q28506206 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor | Q29616727 | ||
| BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis | Q29620466 | ||
| Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia | Q33338309 | ||
| Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. | Q33806087 | ||
| Immunotoxin treatment of cancer | Q34000417 | ||
| Immunotoxin therapy of hematologic malignancies | Q35206377 | ||
| Rapid turnover of mcl-1 couples translation to cell survival and apoptosis | Q35695499 | ||
| Diphtheria toxin entry into cells is facilitated by low pH. | Q36202047 | ||
| The entry of diphtheria toxin into the mammalian cell cytoplasm: evidence for lysosomal involvement | Q36202074 | ||
| Single-chain immunotoxins directed at the human transferrin receptor containing Pseudomonas exotoxin A or diphtheria toxin: anti-TFR(Fv)-PE40 and DT388-anti-TFR(Fv). | Q36689028 | ||
| Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. | Q37163339 | ||
| Bcl-2 inhibitors: small molecules with a big impact on cancer therapy | Q37275477 | ||
| Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. | Q37368203 | ||
| Apoptosis and colorectal cancer: implications for therapy | Q37441730 | ||
| Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity | Q37664951 | ||
| Dual mechanisms of sHA 14-1 in inducing cell death through endoplasmic reticulum and mitochondria. | Q39832035 | ||
| Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies | Q40623388 | ||
| Role of caspases in immunotoxin-induced apoptosis of cancer cells | Q40991218 | ||
| Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells | Q41614148 | ||
| Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines | Q41660848 | ||
| The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. | Q42064781 | ||
| Endogenous Noxa Determines the Strong Proapoptotic Synergism of the BH3-Mimetic ABT-737 with Chemotherapeutic Agents in Human Melanoma Cells. | Q42100332 | ||
| An informatics approach identifying markers of chemosensitivity in human cancer cell lines. | Q42496234 | ||
| Internalized Pseudomonas exotoxin A can exploit multiple pathways to reach the endoplasmic reticulum | Q42804382 | ||
| Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro. | Q42808417 | ||
| Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin | Q44424103 | ||
| Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 | ||
| Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin | Q45070025 | ||
| A phase I trial of the single-chain immunotoxin SGN-10 (BR96 sFv-PE40) in patients with advanced solid tumors | Q47615268 | ||
| Subversion of the Bcl-2 life/death switch in cancer development and therapy. | Q50930237 | ||
| Immunotoxin therapy of cancer | Q56454451 | ||
| The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum | Q56990647 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 2007-2015 | |
| P577 | publication date | 2010-06-29 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol | |
| P478 | volume | 9 |
| Q35230663 | A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer |
| Q87695496 | ABT-737 promotes the dislocation of ER luminal proteins to the cytosol, including pseudomonas exotoxin |
| Q36907540 | Antibody-based therapeutics for the treatment of human B cell malignancies |
| Q36129683 | Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors |
| Q37625758 | Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors |
| Q28553712 | Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins |
| Q41149227 | Clinical targeting recombinant immunotoxins for cancer therapy |
| Q36481165 | Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines |
| Q35018336 | Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. |
| Q39046021 | Combining the antimesothelin immunotoxin SS1P with the BH3-mimetic ABT-737 induces cell death in SS1P-resistant pancreatic cancer cells |
| Q33694949 | Cytolethal distending toxin B as a cell-killing component of tumor-targeted anthrax toxin fusion proteins |
| Q33682689 | Emerging Bcl-2 inhibitors for the treatment of cancer |
| Q37877741 | Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. |
| Q50705733 | Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins. |
| Q37139525 | Immunotoxins: the role of the toxin |
| Q46409297 | Improved Protein Toxin Delivery Based on ATTEMPTS Systems |
| Q35223910 | Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody |
| Q28385366 | Mechanisms of action of therapeutic antibodies for cancer |
| Q26738528 | Mechanisms of drug resistance in colon cancer and its therapeutic strategies |
| Q39426084 | Methylseleninic acid potentiates multiple types of cancer cells to ABT-737-induced apoptosis by targeting Mcl-1 and Bad. |
| Q34085129 | MicroRNA-195 promotes apoptosis in mouse podocytes via enhanced caspase activity driven by BCL2 insufficiency |
| Q28476828 | Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma |
| Q38778443 | Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer. |
| Q35969887 | Targeting malignant B cells with an immunotoxin against ROR1 |
| Q27021990 | The development of immunoconjugates for targeted cancer therapy |
| Q36406637 | The transferrin receptor and the targeted delivery of therapeutic agents against cancer. |
Search more.